Interethnic diversity of NAT2 polymorphisms in Brazilian admixed populations

BMC Genetics

Volumn 11, Issue , 2010, Pages

  Talbot, Jhimmy ^a   Magno, Luiz A V ^a,b   Santana, Cinthia V N ^a   Sousa, Sandra M B ^a   Melo, Paulo R S ^a   Correa, Ronan X ^a   Di Pietro, Giuliano ^a   Rios Santos, Fabrício ^a  

^a DEPARTAMENTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLIZING ENZYME; N ACETYLTRANSFERASE TYPE 2; UNCLASSIFIED DRUG; ARYLAMINE ACETYLTRANSFERASE; NAT2 PROTEIN, HUMAN;

ARTICLE; BRAZIL; CONTROLLED STUDY; ETHNIC DIFFERENCE; ETHNIC GROUP; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; FEMALE; GENETICS; MALE;

ADULT; ARYLAMINE N-ACETYLTRANSFERASE; BRAZIL; ETHNIC GROUPS; FEMALE; HUMANS; MALE; POLYMORPHISM, GENETIC;

EID: 77957262392     PISSN: None     EISSN: 14712156     Source Type: Journal    
DOI: 10.1186/1471-2156-11-87     Document Type: Article

References (43)

1. Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?. Am J Hum Genet 1997, 60:265-271. 1712416, 9012398.
2. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005, 352:2211-2221. 10.1056/NEJMra032424, 15917386.
3. Meyer UA. Polymorphism of human acetyltransferases. Environ Health Prospect 1994, 102(Suppl 6):213-216.
4. Riddle B, Jencks WP. Acetyl-coenzyme A: arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituent on the rate. J Biol Chem 1971, 246:3250-3258.
5. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002, 506-507:65-77.
6. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K, Komuta K, Igarashi T, Azuma J. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000, 4:256-261.
7. Palamanda JR, Hickman D, Ward A, Sim E, Romkes-Sparks M, Unadkat JD. Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with ant opportunistic infection drugs. Drug Metab Dispos 1995, 23:473-477.
8. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human N-acetyltransferase genes: isolation, chromosomal localization and functional expression. DNA Cell Biol 1990, 9:193-203. 10.1089/dna.1990.9.193, 2340091.
9. Hickman D, Pope J, Patil SD, Fakis G, Smelt V, Stanley LA, Payton M, Unadkat JD, Sim E. Expression of arylamine N-acetyltransferase in human intestine. Gut 1998, 42:402-409. 10.1136/gut.42.3.402, 1727045, 9577349.
10. Windmill KF, McKinnon RA, Zhu XY, Gaedigk A, Grant DM, McManus ME. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res 1997, 376:153-160.
11. Evans DA, Manley KA, Mc KV. Genetic control of isoniazid metabolism in man. Br Med J 1960, 2:485-491. 10.1136/bmj.2.5197.485, 2097108, 13820968.
12. Boukouvala S, Sim E. Structural analysis of the genes for human arylamine N-acetyltransferases and characterization of alternative transcripts. Basic Clin Pharmacol Toxicol 2005, 96:343-351. 10.1111/j.1742-7843.2005.pto_02.x, 15853926.
13. Furet Y, Bechtel Y, Le Guellec C, Bechtel PR, Autret-Leca E, Paintaud G. Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism. Therapy 2002, 57:427-431.
14. Spielberg SP. N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 1996, 24:509-519. 10.1007/BF02353477, 9131488.
15. Norton JT, Witschi MA, Luong L, Kawamura A, Ghosh S, Stack MS, Sim E, Avram MJ, Appella DH, Huang S. Synthesis and anticancer activities of 6-amino amonafide derivatives. Anticancer Drugs 2008, 19:23-36. 10.1097/CAD.0b013e3282f00e17, 18043127.
16. Wood AJ. Racial differences in the response to drugs-pointers to genetic differences. N Engl J Med 2001, 344:1394-1396. 10.1056/NEJM200105033441811, 11336055.
17. Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet 2008, 9:21. 10.1186/1471-2156-9-21, 2292740, 18304320.
18. Alves-Silva J, da Silva Santos M, Guimarães PE, Ferreira AC, Bandelt HJ, Pena SD, Prado VF. The ancestry of Brazilian mtDNA lineages. Am J Hum Genet 2000, 67:444-461. 10.1086/303004, 1287189, 10873790.
19. Carvalho-Silva DR, Santos FR, Rocha J, Pena SD. The phylogeography of Brazilian Y-chromosome lineages. Am J Hum Genet 2001, 68:281-286. 10.1086/316931, 1234928, 11090340.
20. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 2003, 100:177-182. 10.1073/pnas.0126614100, 140919, 12509516.
21. Doll MA, Fretland AJ, Deitz AC, Hein DW. Determination of Human NAT2 Acetylator Genotype by Restriction Fragment-Length Polymorphism and Allele-Specific Amplification. Anal Biochem 1995, 231:413-420. 10.1006/abio.1995.9978, 8594994.
22. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003, 25:115-121. 10.1002/gepi.10252, 12916020.
23. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265. 10.1093/bioinformatics/bth457, 15297300.
24. Rodrigues-Lima F, et al. 3 D model of human arylamine N-acetyltransferase 2: structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop. Biochem Biophys Res Commun 2003, 291:116-123.
25. Walraven JM, Zang Y, Trent JO, Hein DW. Structure/function evaluations of single nucleotide polymorphisms in human n-acetyltransferase 2. Curr Drug Metab 2008, 9:471-486. 10.2174/138920008784892065, 2507886, 18680467.
26. Zang Y, Doll MA, Zhao S, States JC, Hein DW. Functional characterization of single nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 2007, 28:1665-1671. 10.1093/carcin/bgm085, 2085371, 17434923.
27. Au WW, Sierra-Torres CH, Cajas-Salazar N, Salama SA. Inheritance of polymorphic metabolizing genes on environmental disease and quality of life. Mutat Res 1999, 428:131-140.
28. Delomenie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics 1996, 6:177-185. 10.1097/00008571-199604000-00004, 9156695.
29. Patin E, Harmant C, Kidd KK, Kidd J, Froment A, Mehdi SQ, Sica L, Heyer E, Quintana-Murci L. Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum Mutat 2006, 27:720. 10.1002/humu.9438, 16786516.
30. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995, 57:581-592. 1801274, 7668286.
31. Agundez JA, Olivera M, Martinez C, Ladero JM, Benitez J. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 1996, 6:423-428. 10.1097/00008571-199610000-00006, 8946474.
32. Lin HJ, Han CY, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet 1993, 52:827-834. 1682080, 8460648.
33. Teixeira RL, Miranda AB, Pacheco AG, Lopes MQ, Fonseca-Costa J, Rabahi MF, Melo HM, Kritski AL, Mello FC, Suffys PN, Santos AR. Genetic profile of the arylamine N-acetyltransferase 2 coding gene among individuals from two different regions of Brazil. Mutat Res 2007, 624:31-40.
34. Jorge-Nebert LF, Eichelbaum M, Griese EU, Inaba T, Arias TD. Analysis of six SNPs of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype using caffeine. Pharmacogenetics 2002, 12:39-48. 10.1097/00008571-200201000-00006, 11773863.
35. Fuselli S, Gilman RH, Chanock SJ, Bonatto SL, De Stefano G, Evans CA, Labuda D, Luiselli D, Salzano FM, Soto G, Vallejo G, Sajantila A, Pettener D, Tarazona-Santos E. Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity. Pharmacogenomics J 2007, 7:144-152. 10.1038/sj.tpj.6500407, 16847467.
36. Santos FR, Pandya A, Tyler-Smith C, Pena SD, Schanfield M, Leonard WR, Osipova L, Crawford MH, Mitchell RJ. The central Siberian origin for native American Y chromosomes. Am J Hum Genet 1999, 64:619-628. 10.1086/302242, 1377773, 9973301.
37. Lell JT, Sukernik RI, Starikovskaya YB, Su B, Jin L, Schurr TG, Underhill PA, Wallace DC. The dual origin and Siberian affinities of Native American Y chromosomes. Am J Hum Genet 2002, 70:192-206. 10.1086/338457, 384887, 11731934.
38. Sabbagh A, Darlu P. Inferring haplotypes at the NAT2 locus: the computational approach. BMC Genet 2005, 6:30. 10.1186/1471-2156-6-30, 1173101, 15932650.
39. Magno LA, Talbot J, Talbot T, Borges SA, Souza RP, Marin LJ, Moreli ML, de Melo PR, Correa RX, Rios Santos F, Di Pietro G. Glutathione s-transferase variants in a brazilian population. Pharmacology 2009, 83:231-236. 10.1159/000205823, 19258736.
40. Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, Picon PD, Santos AR, Teixeira RL, Gregianini TS, Hutz MH, Rossetti ML, Zaha A. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008, 64:673-681. 10.1007/s00228-008-0484-8, 18421452.
41. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K, Komuta K, Igarashi T, Azuma J. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000, 4:256-261.
42. Agundez JA. Polymorphisms of human n-acetyltransferases and cancer risk. Curr Drug Metab 2008, 9:520-531. 10.2174/138920008784892083, 18680472.
43. Di Pietro G, Magno LA, Rios-Santos F. Glutathione S-transferases: an overview in cancer research. Expert Opin Drug Metab Toxicol 2010, 6:153-170. 10.1517/17425250903427980, 20078251.